别名 Antigen MZ2-D、Cancer/testis antigen 1.3、cancer/testis antigen family 1, member 3 + [10] |
简介 Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a as repressor of autophagy (PubMed:20864041, PubMed:31267705). May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex (PubMed:17942928, PubMed:20864041). May play a role in embryonal development and tumor transformation or aspects of tumor progression (PubMed:17942928, PubMed:20864041). In vitro promotes cell viability in melanoma cell lines (PubMed:17942928). Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes (PubMed:8113684). |
靶点 |
作用机制 MAGEA3调节剂 [+1] |
在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 MAGEA3调节剂 [+1] |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 MAGEA3抑制剂 [+3] |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2021-12-15 |
申办/合作机构 |
开始日期2021-12-08 |
申办/合作机构 Cancer Research UK [+1] |
开始日期2021-05-19 |
申办/合作机构 BioNTech SE [+1] |